Failure of MIF-I to affect behavioral responses in patients with parkinson's disease under l-dopa therapy

T. Caraceni, E. A. Parati, F. Girotti, Ivana Celano, Clara Frigerio, Daniela Cocchi, E. E. Müller

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

In eight subjects with Parkinson's disease under an optimal daily dose of l-dopa, acute administration of MIF-I (200 mg i.v.) did not ameliorate either the total disability score or the intellectual test PM 38 when evaluated in comparison with the effect induced by acute administration of a placebo. Also concomitant evaluation of the effect of MIF-I on the secretion of anterior pituitary hormones which are under dopaminergic control i.e., growth hormone and prolactin, did not reveal any potentiation of the l-dopa-induced stimulus.

Original languageEnglish
Pages (from-to)217-222
Number of pages6
JournalPsychopharmacology
Volume63
Issue number3
DOIs
Publication statusPublished - Jan 1979

Fingerprint

MSH Release-Inhibiting Hormone
Dihydroxyphenylalanine
Parkinson Disease
Anterior Pituitary Hormones
Prolactin
Growth Hormone
Placebos
Therapeutics

Keywords

  • Behavioral effects
  • Growth hormone
  • l-dopa
  • MIF-I
  • Parkinson's disease
  • Prolactin

ASJC Scopus subject areas

  • Pharmacology

Cite this

Failure of MIF-I to affect behavioral responses in patients with parkinson's disease under l-dopa therapy. / Caraceni, T.; Parati, E. A.; Girotti, F.; Celano, Ivana; Frigerio, Clara; Cocchi, Daniela; Müller, E. E.

In: Psychopharmacology, Vol. 63, No. 3, 01.1979, p. 217-222.

Research output: Contribution to journalArticle

Caraceni, T, Parati, EA, Girotti, F, Celano, I, Frigerio, C, Cocchi, D & Müller, EE 1979, 'Failure of MIF-I to affect behavioral responses in patients with parkinson's disease under l-dopa therapy', Psychopharmacology, vol. 63, no. 3, pp. 217-222. https://doi.org/10.1007/BF00433553
Caraceni, T. ; Parati, E. A. ; Girotti, F. ; Celano, Ivana ; Frigerio, Clara ; Cocchi, Daniela ; Müller, E. E. / Failure of MIF-I to affect behavioral responses in patients with parkinson's disease under l-dopa therapy. In: Psychopharmacology. 1979 ; Vol. 63, No. 3. pp. 217-222.
@article{8376e552df634ecfa40890f4669a6d74,
title = "Failure of MIF-I to affect behavioral responses in patients with parkinson's disease under l-dopa therapy",
abstract = "In eight subjects with Parkinson's disease under an optimal daily dose of l-dopa, acute administration of MIF-I (200 mg i.v.) did not ameliorate either the total disability score or the intellectual test PM 38 when evaluated in comparison with the effect induced by acute administration of a placebo. Also concomitant evaluation of the effect of MIF-I on the secretion of anterior pituitary hormones which are under dopaminergic control i.e., growth hormone and prolactin, did not reveal any potentiation of the l-dopa-induced stimulus.",
keywords = "Behavioral effects, Growth hormone, l-dopa, MIF-I, Parkinson's disease, Prolactin",
author = "T. Caraceni and Parati, {E. A.} and F. Girotti and Ivana Celano and Clara Frigerio and Daniela Cocchi and M{\"u}ller, {E. E.}",
year = "1979",
month = "1",
doi = "10.1007/BF00433553",
language = "English",
volume = "63",
pages = "217--222",
journal = "Psychopharmacology",
issn = "0033-3158",
publisher = "Springer Verlag",
number = "3",

}

TY - JOUR

T1 - Failure of MIF-I to affect behavioral responses in patients with parkinson's disease under l-dopa therapy

AU - Caraceni, T.

AU - Parati, E. A.

AU - Girotti, F.

AU - Celano, Ivana

AU - Frigerio, Clara

AU - Cocchi, Daniela

AU - Müller, E. E.

PY - 1979/1

Y1 - 1979/1

N2 - In eight subjects with Parkinson's disease under an optimal daily dose of l-dopa, acute administration of MIF-I (200 mg i.v.) did not ameliorate either the total disability score or the intellectual test PM 38 when evaluated in comparison with the effect induced by acute administration of a placebo. Also concomitant evaluation of the effect of MIF-I on the secretion of anterior pituitary hormones which are under dopaminergic control i.e., growth hormone and prolactin, did not reveal any potentiation of the l-dopa-induced stimulus.

AB - In eight subjects with Parkinson's disease under an optimal daily dose of l-dopa, acute administration of MIF-I (200 mg i.v.) did not ameliorate either the total disability score or the intellectual test PM 38 when evaluated in comparison with the effect induced by acute administration of a placebo. Also concomitant evaluation of the effect of MIF-I on the secretion of anterior pituitary hormones which are under dopaminergic control i.e., growth hormone and prolactin, did not reveal any potentiation of the l-dopa-induced stimulus.

KW - Behavioral effects

KW - Growth hormone

KW - l-dopa

KW - MIF-I

KW - Parkinson's disease

KW - Prolactin

UR - http://www.scopus.com/inward/record.url?scp=0018413476&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018413476&partnerID=8YFLogxK

U2 - 10.1007/BF00433553

DO - 10.1007/BF00433553

M3 - Article

VL - 63

SP - 217

EP - 222

JO - Psychopharmacology

JF - Psychopharmacology

SN - 0033-3158

IS - 3

ER -